249 related articles for article (PubMed ID: 32541473)
21. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
Kang Z; Li Z; Duan C; Wu T; Xun M; Ding Y; Zhang Y; Zhang L; Yin Y
Pediatr Nephrol; 2015 Jul; 30(7):1121-9. PubMed ID: 25773534
[TBL] [Abstract][Full Text] [Related]
22. Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroids plus cyclophosphamide treatment efficacy in IgA nephropathy.
Fang J; Li W; Li D; Tan Z
Chin Med J (Engl); 2014; 127(9):1710-4. PubMed ID: 24791879
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
Liu T; Wang Y; Mao H; Yang L; Zhan Y
Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.
Jia Q; Ma F; Yang X; Li L; Liu C; Sun R; Li R; Sun S
Clin Exp Nephrol; 2022 Mar; 26(3):257-265. PubMed ID: 34724588
[TBL] [Abstract][Full Text] [Related]
25. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
[TBL] [Abstract][Full Text] [Related]
26. Pro: STOP immunosuppression in IgA nephropathy?
Pozzi C
Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study.
Hu Y; Huang Z; Cao Q; Chen B; Xu S; Qiu W; You X; Zhang J; Chen C
Ren Fail; 2023; 45(2):2267138. PubMed ID: 37850851
[TBL] [Abstract][Full Text] [Related]
28. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
[TBL] [Abstract][Full Text] [Related]
29. Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.
Yang Y; Tang X; Yang Y; Li X; Li L; Huang K; Li Y; Li J; Fu P
Ren Fail; 2020 Nov; 42(1):629-637. PubMed ID: 32660366
[TBL] [Abstract][Full Text] [Related]
30. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
Tang Y; He H; Sun W; Hu P; Chen X; Xu X
Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
[TBL] [Abstract][Full Text] [Related]
31. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
Moriyama T; Nakayama K; Ochi A; Amemiya N; Tsuruta Y; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
Clin Exp Nephrol; 2012 Apr; 16(2):231-7. PubMed ID: 22038185
[TBL] [Abstract][Full Text] [Related]
32. The Association of Glomerular Glucocorticoid Receptor Expression with Responsiveness to Corticosteroid Treatment in IgA Nephropathy.
Kee YK; Nam BY; Jhee JH; Park JT; Lim BJ; Yoo TH; Kang SW; Jeong HJ; Han SH
Am J Nephrol; 2019; 50(3):187-195. PubMed ID: 31408863
[TBL] [Abstract][Full Text] [Related]
33. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
35. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
[TBL] [Abstract][Full Text] [Related]
36. Clinical Response to Intestine-targeted Steroid Therapy in Biopsy-proven Immunoglobulin A Nephropathy.
Lingaraj U; Mallapur S; Viswanathan A; Vankalakunti M
Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):755-760. PubMed ID: 38018717
[TBL] [Abstract][Full Text] [Related]
37. Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience.
Mohd R; Mohammad Kazmin NE; Abdul Cader R; Abd Shukor N; Wong YP; Shah SA; Alfian N
PLoS One; 2021; 16(4):e0249592. PubMed ID: 33831052
[TBL] [Abstract][Full Text] [Related]
38. Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy.
Fabiano RCG; de Almeida Araújo S; Bambirra EA; Oliveira EA; Simões E Silva AC; Pinheiro SVB
Pediatr Nephrol; 2017 Jul; 32(7):1211-1220. PubMed ID: 28233100
[TBL] [Abstract][Full Text] [Related]
39. Crescentic IgA nephropathy in children.
Shima Y; Nakanishi K; Hama T; Mukaiyama H; Sato M; Tanaka Y; Tanaka R; Kaito H; Nozu K; Sako M; Iijima K; Yoshikawa N
Pediatr Nephrol; 2020 Jun; 35(6):1005-1014. PubMed ID: 31993782
[TBL] [Abstract][Full Text] [Related]
40. Spontaneous remission in adult patients with IgA nephropathy treated with conservative therapy.
Sato H; Ichikawa D; Okada E; Suzuki T; Watanabe S; Shirai S; Shibagaki Y
PLoS One; 2021; 16(5):e0251294. PubMed ID: 34043669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
